ABSTRAKT

This study optimized the radiolabeling of cisplatin with technetium-99m (^99mTc) and evaluated its biodistribution in an experimental model of lung carcinogenesis. The percentage labeling of cisplatin with ^99mTc was assessed using an ascending chromatographic technique. For biodistribution studies, male rats were divided into 2 groups. The control group received normal saline intratracheally, whereas the treatment group received intratracheal administration of carcinogen 7,12-dimethylbenz(a)anthracene (DMBA) at a dose of 20 mg/kg body weight. The resulting radiopharmaceutical (^99mTc-cisplatin) showed 98% labeling efficiency and was found to be stable for up to 6 hours both in both serum and saline under normal conditions. The blood clearance of the ^99mTc-cisplatin followed a biphasic release pattern whereby a fast-release phase was observed at 35 seconds and a slow-release phase was observed after 30 minutes of drug administration. The biodistribution studies of control and treated animals revealed high uptake of ^99mTc-cisplatin by the liver and slow excretion via the kidneys. However, a time-dependent increase in the lung-to-muscle specific uptake ratio was observed in DMBA-treated rats. The study concluded that ^99mTc-cisplatin possesses selectivity toward cancerous lung tissue and can be explored further for its diagnostic potential in the detection of lung cancer and the evaluation of treatment response.